Cargando…
Cancer-specific T cell receptor isolation for cancer immunotherapy
Autores principales: | Baker, Debbie Emma, Hibbert, Linda, Weigand, Luise, Paston, Samantha, Ryan, Ruth, Donnellan, Zoe, Simmons, Ruth, Hale, Kathy, Conlon, Louise, Dukes, Joseph, Clark, Vanessa, Boudousquie, Caroline, Bossi, Giovanna, Hickman, Emma, Powlesland, Alex, Vuidepot, Annelise, Hassan, Namir, Jakobsen, Bent |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649499/ http://dx.doi.org/10.1186/2051-1426-3-S2-P380 |
Ejemplares similares
-
ImmTACs: bi-specific TCR-anti-CD3 fusions for targeted tumour killing
por: Donnellan, Zoe, et al.
Publicado: (2015) -
Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy
por: Raman, Marine C C, et al.
Publicado: (2016) -
An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules
por: Harper, Jane, et al.
Publicado: (2018) -
Elimination of Latently HIV-infected Cells from Antiretroviral Therapy-suppressed Subjects by Engineered Immune-mobilizing T-cell Receptors
por: Yang, Hongbing, et al.
Publicado: (2016) -
Polyfunctional response by ImmTAC (IMCgp100) redirected CD8(+) and CD4(+) T cells
por: Boudousquie, Caroline, et al.
Publicado: (2017)